Cellectar Biosciences (CLRB) Net Equity Issued and Repurchased (2011 - 2021)
Cellectar Biosciences (CLRB) posted Net Equity Issued and Repurchased of -$1.0 for Q4 2021, down 100.0% sequentially from $69000.0 in Q2 2021, and down 100.0% YoY from $41.5 million in Q4 2020.
Cellectar Biosciences (CLRB) Net Equity Issued and Repurchased (2011 - 2021) Analysis & Trends
Cellectar Biosciences has reported Net Equity Issued and Repurchased for 10 years, with the latest figure at -$1.0 in Q4 2021.
- Quarterly Net Equity Issued and Repurchased fell 100.0% year-over-year to -$1.0 in Q4 2021, while the trailing twelve-month figure through Dec 2021 was $41.5 million (changed 0.17% YoY) and the FY2022 annual result came in at $9.6 million, up 27459.01% from the prior year.
- Net Equity Issued and Repurchased slipped to -$1.0 in Q4 2021 per CLRB's latest filing, from $69000.0 in the prior quarter.
- Over five years, Net Equity Issued and Repurchased peaked at $41.5 million in Q4 2020 and troughed at -$1.0 in Q4 2021.
- A 4-year average of $11.1 million and a median of $4.9 million in 2017 frame the typical range for Net Equity Issued and Repurchased.
- The sharpest annual moves came in 2017 and 2021: Net Equity Issued and Repurchased dropped 1.72% in 2017, then sank 100.0% in 2021.
- Over 4 years, Net Equity Issued and Repurchased stood at $4.9 million in 2017, then jumped by 85.0% to $9.1 million in 2018, then jumped by 356.83% to $41.5 million in 2020, then slumped by 100.0% to -$1.0 in 2021.
- According to Business Quant data, Net Equity Issued and Repurchased over the past three periods registered -$1.0, $69000.0, and $41.5 million for Q4 2021, Q2 2021, and Q4 2020 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Equity Issued and Repurchased (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 49.20 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Cellectar Biosciences | 6.73 Mn | 6.73 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2021 | -1.00 |
| Dec 31, 2021 | -1.00 |
| Jun 30, 2021 | 69,000.00 |
| Jun 30, 2021 | 69,000.00 |
| Dec 31, 2020 | 41.46 Mn |
| Dec 31, 2020 | 41.46 Mn |
| Sep 30, 2018 | 9.08 Mn |
| Sep 30, 2018 | 9.08 Mn |
| Dec 31, 2017 | 4.91 Mn |
| Dec 31, 2017 | 4.91 Mn |
| Dec 31, 2016 | 4.99 Mn |
| Dec 31, 2016 | 4.99 Mn |
| Dec 31, 2015 | 3.30 Mn |
| Dec 31, 2015 | 3.30 Mn |
| Sep 30, 2014 | 12.40 Mn |
| Sep 30, 2014 | 12.40 Mn |
| Mar 31, 2013 | 4.98 Mn |
| Mar 31, 2013 | 4.98 Mn |
| Dec 31, 2012 | 1.97 Mn |
| Dec 31, 2012 | 1.97 Mn |